Thermo Fisher Scientific Inc.
NYSE: TMO
Stock price
698.05 USD
(+10.26%) 5 years
Financial Performance
5Y price score: 15
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 381.3%
%
ㅤ
By default your notes are visible only to you.
435.2
52-week range
711.8
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.9 %
Dividend Yield TTM
0.3 %
Market cap $
$ 258,102
Price / Earnings TTM
36.8
Price / Book TTM
4.7
PEG TTM
5
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
25.3 %
11.4 %
381.3 %
Free cash flow per share growth
17.3 %
(2.3) %
180.2 %
Earnings per share growth
8.7 %
11 %
260.6 %
Founded: 1,956
Employees: 125,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q3 (Oct 21, 2026)
1) Financial Performance Overview
- Revenue grew 9% YoY to $12.14 billion.
- Adjusted operating income increased 15% to $2.97 billion, with an adjusted operating margin of 24.5%, up 120 basis points.
- Adjusted EPS rose 15% to $6.68 per share.
- Organic revenue growth was 6%, with a strong performance in Pharma Services and clinical research.
2) Segment Results and Market Dynamics
- Pharma and Biotech: High single-digit growth, driven by Pharma Services and clinical research.
- Academic and Government: Revenue was flat, with strong demand in chromatography and mass spectrometry.
- Industrial and Applied: High single-digit growth, led by electron microscopy.
- Diagnostics and Healthcare: Low single-digit growth, primarily from transplant diagnostics.
- Overall, improved end-market conditions continued from Q2 into Q3.
3) Strategic Initiatives and Innovations
- Launched several new technologies, including the Orbitrap Isora mass spectrometer and the EMPAD G2 electron detector.
- Continued deployment of AI technology across products and services, enhancing customer workflows and productivity.
- Opened an AI-Automation Innovation Center in South Korea to collaborate with customers on next-gen scientific workflows.
- Progressing with the Clario acquisition, which is expected to deliver revenue synergies.
4) Guidance and Future Outlook
- Raised full-year revenue guidance to $47.7 billion-$48.2 billion, reflecting 7%-8% growth over 2025.
- Adjusted EPS guidance increased to $25.13-$25.43, representing 10%-11% growth.
- Organic revenue growth for the full year is now expected to be 4%.
- The company anticipates continued strong operational performance and investments to drive future growth.
5) Investor Considerations
- The call did not provide specific details on the competitive landscape or potential market share gains from AI initiatives.
- Future updates on AI's impact on growth will be discussed in the next investor day.
Bottom line: Thermo Fisher Scientific delivered strong Q3 results, driven by robust growth in Pharma Services and strategic innovations. The raised guidance reflects confidence in continued operational strength and market recovery, positioning the company well for future growth.
Annual Reports, Presentations And IR Contacts
Go to the websiteThermo Fisher Scientific Inc. — Financial Overview, Stock Price, Market Cap
Thermo Fisher Scientific Inc. is a company. Founded in 1956. As of October 30, 2026, the company's market capitalization is $258102092992 with a current stock price of $698.05.